First-in-human trial of CRISPR gene-editing therapy safely lowered cholesterol, triglycerides
November 08, 2025
November 08, 2025
DALLAS, Texas, Nov. 8 [Category: Health Care] -- The American Heart Association posted the following news release:
* * *
First-in-human trial of CRISPR gene-editing therapy safely lowered cholesterol, triglycerides
*
Research Highlights:
* In a Phase 1, first-in-human trial, a one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like protein 3 (ANGPTL3) was safe and reduced LDL cholesterol by nearly . . .
* * *
First-in-human trial of CRISPR gene-editing therapy safely lowered cholesterol, triglycerides
*
Research Highlights:
* In a Phase 1, first-in-human trial, a one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like protein 3 (ANGPTL3) was safe and reduced LDL cholesterol by nearly . . .